Jay Matushak - 12 May 2025 Form 4 Insider Report for NeueHealth, Inc. (NEUE)

Role: Chief Financial Officer
Signature: /s/ Eric Halverson for Jay Matushak, Attorney-in-Fact
Issuer symbol: NEUE
Transactions as of: 12 May 2025
Net transactions value: -$3,191
Form type: 4
Filing time: 14 May 2025, 17:21:00 UTC
Previous filing: 13 May 2025
Next filing: 14 Oct 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Matushak Jay	Chief Financial Officer	C/O NEUEHEALTH, INC., 8000 NORMAN CENTER DRIVE, SUITE 900, MINNEAPOLIS	/s/ Eric Halverson for Jay Matushak, Attorney-in-Fact	14 May 2025	0001977975

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NEUE	Common Stock	Sale	$3,191	-472	-1.2%	$6.76	40,556	12 May 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were sold by the reporting person to cover tax withholding obligations upon the vesting of restricted stock units and were not discretionary transactions by the reporting person.
F2	The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.67 to $6.83 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

These shares were sold by the reporting person to cover tax withholding obligations upon the vesting of restricted stock units and were not discretionary transactions by the reporting person.

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.67 to $6.83 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.